Amneal Pharmaceuticals, Inc. seems fundamentally undervalued, with a market cap significantly lower than peers despite similar revenue levels, suggesting potential for substantial stock price ...

Anthony Dimeo; Head-Investor Relations; Amneal Pharmaceuticals Inc. Chirag Patel; President, Co-Chief Executive Officer, Co-Founder, Director; Amneal Pharmaceuticals Inc. Chintu Patel; Co-Chief ...

Explore Amneal Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for AMRX. Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion ...

Amneal Pharmaceuticals (AMRX) shares rallied 6% in the last trading session to close at $8.30. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the fourth quarter and full year ended December ...

JP Morgan upgraded Amneal to Overweight, raising its price target to $12, citing strong generics growth and expanding biosimilar adoption. How to Spot the Market Bottom: Matt Maley has navigated ...

BRIDGEWATER, N.J. (AP) — BRIDGEWATER, N.J. (AP) — Amneal Pharmaceuticals, Inc. (AMRX) on Friday reported a loss of $31.1 million in its fourth quarter. The Bridgewater, New Jersey-based ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and mAbxience ...

Good morning and welcome to the Amneal Pharmaceuticals Fourth Quarter 2024 Earnings Call. I'd now turn the call over to Amneal's Head of Investor Relations, Tony DiMeo. Please go ahead.